Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics
ObjectivesPosterior reversible encephalopathy syndrome (PRES) is a rare but potentially severe complication of VEGF-pathway inhibition. A recent FAERS analysis supported PRES as a probable class effect of angiogenesis inhibitors but found no association with continuous VEGFR affinity, did not formal...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2026-07-01
|
| Series: | Frontiers in Pharmacology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1887454/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|